Voglow-GM1 Tab

Composition

Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.3mg)

Uses of Voglow-GM1 Tab

Treatment of Type 2 diabetes mellitus

• •In Treatment of Type 2 diabetes mellitus Voglow 0.3 GM1 Tablet helps control high blood glucose levels after meals and supports better overall diabetes management. The medicine lowers the risk of serious complications of diabetes
• •such as kidney damage
• •vision problems
• •nerve issues
• •and limb loss. It also helps reduce the risk of death from cardiovascular disease in people with type 2 diabetes who already have heart disease. Regular use of Voglow 0.3 GM1 Tablet
• •along with a healthy diet and exercise
• •supports long-term health and helps you maintain a more stable and active life.

How it works

Voglow 0.3 GM1 Tablet is a combination of three antidiabetic medicines: glimepiride, metformin, and voglibose. They work by different mechanisms to provide better control of blood sugar when single or dual therapy is not effective. Glimepiride is a sulfonylurea that works by increasing the amount of insulin released by the pancreas to lower the blood glucose. Metformin is a biguanide that lowers glucose production in the liver, delays glucose absorption from the intestines, and increases the body's sensitivity to insulin. Voglibose is an alpha-glucosidase inhibitor that prevents the breakdown of complex sugars into simple sugars such as glucose. This prevents the blood glucose levels from rising to very high levels after meals.